Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.
强生公司（NYSE:JNJ）在周三报告了第二季度调整后的每股收益为2.82美元，同比增长10.2%，超出2.70美元的共识预期。
RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China. They expect the third quarter to follow typical seasonal patterns without backlog issues, with robust MedTech markets projected for 2024 and beyond.
RBC资本市场预计，在中国以外的公司将会迎来有利的第二季度环境。他们预期第三季度将遵循典型的季节性模式，没有拖欠问题，预计医疗技术市场将在2024年及以后保持强劲。
Johnson & Johnson maintains its consistent M&A strategy, affirming continuity even after acquiring Shockwave Medical. The company asserts confidence in its ability to explore diverse opportunities moving forward.
强生公司在收购Shockwave Medical之后，仍坚持其一贯的并购策略，确认在未来继续探索多样化的机会上有信心，强调其对并购的长期考虑，优先考虑可持续发展的增长而非短期利润。
Johnson & Johnson has stated that while it is open to opportunities across all sectors and sizes, it prefers areas with existing expertise and capabilities.
强生公司表示，虽然它对所有板块和规模的机会都持开放态度，但它更喜欢已有专业知识和能力的领域。
It emphasized its long-term approach to mergers and acquisitions, prioritizing sustainable growth over short-term gains.
它强调了其对于并购的长期考虑，优先考虑可持续发展的增长而非短期利润。
The RBC analyst adds that in the second quarter, both businesses showed sequentially increasing growth on a stacked 2-year basis, indicating improved fundamentals compared to the first quarter.
RBC的分析师补充道，在第二季度，这两家公司在两年期间的基础上序贯增长，表明相对于第一季度的基本面有所改善。
Johnson & Johnson anticipates faster sales growth in its Medical Technology sector in the second half of 2024. However, it foresees a slowdown in sales growth for Innovative Medicine, mainly due to the entry of a biosimilar for Stelara in Europe.
强生公司预计，其医疗技术板块在2024年下半年将实现更快的销售增长，但是，由于Stelara的类同生物制品进入欧洲市场，它预见到创新药业务的销售增长将放缓。
RBC Capital maintains the Outperform rating with a price target of $175.
RBC Capital维持Outperform评级，目标价为175美元。
Truist Securities says the management noted Imbruvica continues to experience competitive pressure, including Jaypirca, which was developed by Eli Lilly And Co (NYSE:LLY).
Truist Securities表示，管理层指出Imbruvica继续受到竞争压力，包括Eli Lilly And Co (NYSE:LLY)开发的Jaypirca。
"In our view, this may reflect physician demand for novel options that can address resistance to older and less efficacious molecules such as Imbruvica," Truist analyst writes.
"在我们看来，这可能反映了医生对能够解决对Imbruvica等旧药效不佳的分子的抵抗力的新式选择的需求，"Truist分析师写道。
Johnson & Johnson reports strong Tecvayli demand despite slower growth following FDA approval for a longer dosing interval. Pfizer Inc's (NYSE:PFE) Elrexfio allows biweekly dosing after week 24, contrasting with Tecvayli's weekly dosing regimen.
尽管FDA批准了较长剂量间隔的Tecvayli，但强生公司报告称其对Tecvayli的需求强劲，并且Pfizer Inc（NYSE:PFE）的Elrexeo允许在第24周后进行双周剂量，与Tecvayli每周一次的剂量方案形成对比。
This suggests a potential positive signal for Elrexfio. Meanwhile, attention is on Regeneron Pharmaceutical Inc's (NASDAQ:REGN) linvoseltamab, anticipated to offer a best-in-class profile with promising response rates (71% ORR and 46% CR or better).
这表明Elrexfio有可能取得积极的信号。同时，人们关注着Regeneron Pharmaceutical Inc（NASDAQ:REGN）的linvoseltamab，预计将提供最佳类别的特点，具有有前途的反应率（71%的ORR和46%的CR或更好）。
Price Action: JNJ Stock is down 0.42% at $155.92 at last check Thursday.
JNJ股票周四最后一次检查下跌0.42%，报155.92美元。
Photo via Shutterstock
图片来自shutterstock。